ViroPharma Incorporated

EXTON, Pa., May 9, 2013 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that Robert Doody, director of investor relations, will present at the 2013 Bank of America Merrill Lynch Healthcare Conference at 11:20 AM PT (2:20 PM ET) on Tuesday, May 14, 2013. The conference ... read more

EXTON, Pa., May 1, 2013 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced financial results for the first quarter of 2013. Net sales were $107 million for the first quarter ended March 31, 2013 as compared to $136 million in the comparative period of 2012. The decline in net ... read more

EXTON, Pa., April 25, 2013 /PRNewswire/ -- ViroPharma Incorporated's (Nasdaq: VPHM) first quarter financial results for 2013 are expected to be released on Wednesday, May 1, 2013 before the open of the U.S. financial markets. The company will host a conference call and live audio webcast at 9:00 ... read more

EXTON, Pa., April 22, 2013 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM), an international biopharmaceutical company committed to developing and commercializing innovative products that address unmet medical needs and rare diseases, today announced the results of a Phase 2 study of VP20621 (non-toxigenic Clostridium difficile; NTCD) a novel treatment approach for ... read more

EXTON, Pa., Feb. 27, 2013 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) reported today its financial results for the fourth quarter and year ended December 31, 2012. In 2012, we: -- Achieved $428 million in annual net product sales, highlighted by $327 ... read more

EXTON, Pa., Feb. 22, 2013 /PRNewswire/ -- ViroPharma Incorporated's (Nasdaq: VPHM) fourth quarter and full year financial results for 2012 are expected to be released on Wednesday, February 27, 2013 before the open of the U.S. financial markets. The company will host a conference call and live audio ... read more

EXTON, Pa., Feb. 11, 2013 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that Charles Rowland, vice president and chief financial officer of ViroPharma, will present at the 2013 Leerink Swann Global Healthcare Conference at 11:30 AM ET on Thursday, February 14, 2013. The conference is ... read more

EXTON, Pa., Jan. 16, 2013 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced the publication of data demonstrating that use of Cinryze(®) (C1 esterase inhibitor [human]) in pediatric patients provided relief from symptoms of hereditary angioedema (HAE) attacks and reduced the rate of attacks. HAE is a ... read more

EXTON, Pa., Jan. 7, 2013 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that Vincent Milano, president and chief executive officer of ViroPharma, will provide an overview of the company's business, including additional maribavir clinical trial data, during the 31(st) Annual J.P. Morgan Healthcare Conference. The presentation will be webcast ... read more

EXTON, Pa., Dec. 12, 2012 /PRNewswire/ -- ViroPharma Incorporated (NASDAQ: VPHM) today announced the launch of a new unbranded campaign focusing on moments lost to hereditary angioedema (HAE) attacks to raise awareness among physicians of the emotional and psychological burden of HAE on patients' lives. HAE is ... read more

EXTON, Pa., Nov. 29, 2012 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that Vincent Milano, president and chief executive officer of ViroPharma, will present at the Deutsche Bank dbAccess BioFest 2012 Conference at 9:00 AM ET on Monday, December 3, 2012. The conference is being ... read more